在患有局部晚期非小细胞肺癌的患者同时接受化疗和免疫检查点抑制后肺炎
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
概括
在接受联合化疗和免疫检查点抑制 (CRT-ICI) 的肺癌患者中,肺炎风险与辐射剂量和先前存在的肺病有关. 这种并发症显著增加死亡率,即使不是致命的.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 肺部病理学 肺部病理学
背景情况:
- 肺炎是化学辐射和免疫检查点抑制 (CRT-ICI) 在局部晚期非小细胞肺癌 (LA-NSCLC) 的严重并发症.
- 识别风险因素和生存影响对于管理这种毒性至关重要.
研究的目的:
- 在接受CRT-ICI治疗的LA-NSCLC患者中识别肺炎的风险因素.
- 为了确定肺炎对患者存活率的影响.
主要方法:
- 对140名用CRT-ICI (杜尔瓦卢马布) 治疗的LA-NSCLC患者的回顾性图表审查.
- 多变量致病特异性危险模型,用于2级以上肺炎的危险因素.
- 肺炎多变量Cox比例危险模型对死亡率的影响.
主要成果:
- 2级以上肺炎的累积发病率为23%.
- 肺炎风险增加与更高的平均肺辐射剂量和治疗前间歇性肺病相关.
- 级别≥2和高级肺炎显著与所有原因死亡率的增加有关.
结论:
- 平均肺辐射剂量和间歇性肺病是接受CRT-ICI的LA-NSCLC患者肺炎的关键风险因素.
- 肺炎,即使不是致命的,也与这种患者群体的死亡率大幅增加有关.
相关概念视频
Pneumonia I: Introduction
273
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
273
Pneumonia V: Nursing management and Prevention
2.2K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.2K
Pneumonia III: Complications and Assessment
267
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
267
Pneumonia IV: Management
359
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359
Tumor Immunotherapy
558
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558
Pneumonia II: Pathophysiology
342
The pathophysiology of pneumonia involves the following steps:
342


